QuellTX Logo


Quell Pipeline


Research & Preclinical Development

Phase 1/2


Discovery: Liver transplantation QEL-001
Liver transplantation QEL-001
Discovery: Undisclosed Program QEL-002
Undisclosed Program QEL-002
Discovery: Multiple Undisclosed Research Programs
Multiple Undisclosed Research Programs

The History of Immunosuppression

Since the transformational introduction of liver transplantation in the 1980s, there has been hope for patients with end-stage liver disease. Liver transplantation however is still far from the full cure it was intended to be.

As the transplanted organ is a foreign body, the immune system would naturally reject the organ. To prevent this, patients receive a cocktail of immunosuppressive medications such as corticosteroids, calcineurin inhibitors (such as tacrolimus), plus an antiproliferative agent (such as mycophenolate mofetil). However, this cocktail of medications is extremely potent and suppresses the patient’s immune system globally, leaving the patient open to attack by pathogens which cause serious infections. Importantly, global immunosuppression can also reduce the body’s natural defence against malignancy, namely, ‘immune surveillance’, leaving a patient open to develop cancer due to it not being recognised and cleared by the body.

Our Approach to Treat a Range of Immune Dysregulations

At Quell, we are looking beyond the era of global immunosuppression, and are developing therapies for a range of immune dysregulations, including autoimmunity, inflammatory conditions, and solid organ transplantation. In transplantation our goal is to achieve tolerance, enabling patients to live with their transplanted liver without taking immunosuppressive medication; finally making transplantation the FULL cure it was always intended to be.